Kaunzner UW, Salamon E, Pentsova E, Rosenblum M, Karimi S, Nealon N, Lavi E, Jamieson DG.
2017.
An Acute Disseminated Encephalomyelitis-Like Illness in the Elderly: Neuroimaging and Neuropathology Findings.. J Neuroimaging. 27(3):306-311.
Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH et al..
2017.
Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.. J Magn Reson Imaging. 46(4):951-971.
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..
2016.
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.
Eskreis-Winkler S, Zhou D, Liu T, Gupta A, Gauthier SA, Wang Y, Spincemaille P.
2017.
On the influence of zero-padding on the nonlinear operations in Quantitative Susceptibility Mapping.. Magn Reson Imaging. 35:154-159.
Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..
2017.
Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.
Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon N, Vartanian T, Perumal J.
2016.
A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.